MAM
ESPR

Monaco Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Monaco Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-243,642
Closed -$728K – 68
2023
Q4 		$728K Sell
243,642
-928,137
-79% -$1.2M 0.21% 60
2023
Q3 		$1.15M Buy
1,171,779
+476,477
+69% +$689K 0.34% 46
2023
Q2 		$966K Buy
695,302
+551,940
+385% +$771K 0.27% 48
2023
Q1 		$228K Sell
143,362
-326,738
-70% -$1.69M 0.07% 62
2022
Q4 		$2.93M Buy
470,100
+210,100
+81% +$1.5M 0.88% 32
2022
Q3 		$1.74M Buy
260,000
+87,500
+51% +$601K 0.67% 30
2022
Q2 		$1.1M Sell
172,500
-246,762
-59% -$1.4M 0.48% 39
2022
Q1 		$1.95M Sell
419,262
-80,738
-16% -$346K 0.77% 24
2021
Q4 		$2.5M Buy
+500,000
New +$4M 0.62% 22

Other funds holding ESPR

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Monaco Asset Management's ESPR Position: Q1 2024 in Review

Monaco Asset Management sold out of Esperion Therapeutics (ESPR) in Q1 2024, closing a stake of 243,642 shares — an estimated $728K sold.

Monaco Asset Management first reported a position in ESPR in Q4 2021 and held it in 9 quarters. The position peaked at $2.93M in Q4 2022. 153 funds tracked by Wall St. Rank hold ESPR as of Q1 2024.

  • Monaco Asset Management reported no remaining Esperion Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Monaco Asset Management sold 243,642 Esperion Therapeutics shares in Q1 2024, an estimated $728K.
  • Monaco Asset Management first reported a position in Esperion Therapeutics in Q4 2021 and held it in 9 quarters.
  • Monaco Asset Management's Esperion Therapeutics position peaked at $2.93M in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2024.

Based on Monaco Asset Management's 13F filing for Q1 2024, filed 9 May 2024.